ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

JW Pharmaceutical and Shenzhen Salubris Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

JW PharmaceuticalShenzhen Salubris Pharmaceuticals
studies on the registry7749
open to participants now619
phase 3 studies under way20
reach primary completion within a year38
programswith a study of their own in two years1720

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJW PharmaceuticalShenzhen Salubris Pharmaceuticals
Phase 1

JW Pharmaceutical: 12 of its 17 programs at phase 1

  1. JW0061phase 1
  2. JW0107phase 1
  3. Treatment A_Period 1phase 1
  4. Treatment A_Period 2phase 1
  5. Treatment A_Period 3phase 1

and 7 more — sign in to see them all

71%

Shenzhen Salubris Pharmaceuticals: 8 of its 20 programs at phase 1

  1. Once Daily (QD), Multiple Ascending Dose (MAD)phase 1
  2. Reference Groupphase 1
  3. SAL0123phase 1
  4. SAL0133phase 1
  5. SAL0167phase 1

and 3 more — sign in to see them all

40%
Phase 200%

Shenzhen Salubris Pharmaceuticals: 5 of its 20 programs at phase 2

  1. SAL0140phase 2
  2. GW906phase 2
  3. JK07phase 2
  4. SAL0137phase 2
  5. SAL0150 dose 1phase 2
25%
Phase 3

JW Pharmaceutical: 3 of its 17 programs at phase 3

  1. epaminuradphase 3
  2. jw0108phase 3
  3. JW0108 + C2407phase 3
18%

Shenzhen Salubris Pharmaceuticals: 6 of its 20 programs at phase 3

  1. SAL-0951phase 3
  2. SAL0120phase 3
  3. SAL056phase 3
  4. SAL003phase 3
  5. SAL067phase 3

and 1 more — sign in to see them all

30%
Approved, new studies

JW Pharmaceutical: 2 of its 17 programs at approved, new studies

  1. anagliptinapproved, new study
  2. Ezetimibeapproved, new study
12%

Shenzhen Salubris Pharmaceuticals: 1 of its 20 programs at approved, new studies

  1. enarodustatapproved, new study
5%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
JW Pharmaceutical2 readouts · 1 phase 3·

JW Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion

  1. JW0061phase 1 · Dec 31 · NCT07514780
··

JW Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. anagliptinapproved, new study · Mar 31 · NCT07442006
·······
Shenzhen Salubris Pharmaceuticals5 readouts · 1 phase 3·

Shenzhen Salubris Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. SAL0137phase 2 · Dec 12 · NCT07729475
··

Shenzhen Salubris Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. SAL0140phase 2 · Mar 1 · NCT07654140
··

Shenzhen Salubris Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. enarodustatapproved, new study · Jun 0 · NCT07079579

Shenzhen Salubris Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. SAL0167phase 1 · Jul 31 · NCT07722299
··

Shenzhen Salubris Pharmaceuticals, Oct ’27: 1 program whose next study reaches primary completion

  1. GW906phase 2 · Oct 0 · NCT07835984
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

JW Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Shenzhen Salubris Pharmaceuticals

New programs 2

  • SAL0150 dose 1phase 2 · first study · Nov 2 · Diabetes Mellitus, Type 2
  • GW906phase 2 · first study · Sep 17 · Hypertension

Reached a new phase 1

  • SAL0120phase 3 · Aug 24 · Hypertension

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionJW PharmaceuticalShenzhen Salubris Pharmaceuticals
Hypertensionboth · compare here

JW Pharmaceutical in Hypertension: 1 program

  1. Ezetimibeapproved, new study

Their studies: JW Pharmaceutical’s studies of Hypertension in search

Shenzhen Salubris Pharmaceuticals in Hypertension: 3 programs

  1. SAL0120phase 3
  2. SAL0140phase 2
  3. GW906phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Hypertension in search

Diabetes Mellitus, Type 2both · compare here

JW Pharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. anagliptinapproved, new study

Their studies: JW Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Shenzhen Salubris Pharmaceuticals in Diabetes Mellitus, Type 2: 2 programs

  1. SAL067phase 3
  2. SAL0150 dose 1phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Hyperlipidemiasboth · compare here

JW Pharmaceutical in Hyperlipidemias: 1 program

  1. Ezetimibeapproved, new study

Their studies: JW Pharmaceutical’s studies of Hyperlipidemias in search

Shenzhen Salubris Pharmaceuticals in Hyperlipidemias: 2 programs

  1. SAL003phase 3
  2. SAL0167phase 1

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Hyperlipidemias in search

Atherosclerosisboth · compare here

JW Pharmaceutical in Atherosclerosis: 1 program

  1. Ezetimibeapproved, new study

Their studies: JW Pharmaceutical’s studies of Atherosclerosis in search

Shenzhen Salubris Pharmaceuticals in Atherosclerosis: 1 program

  1. SAL0137phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Atherosclerosis in search

Hypercholesterolemiaboth · compare here

JW Pharmaceutical in Hypercholesterolemia: 1 program

  1. Ezetimibeapproved, new study

Their studies: JW Pharmaceutical’s studies of Hypercholesterolemia in search

Shenzhen Salubris Pharmaceuticals in Hypercholesterolemia: 1 program

  1. SAL003phase 3

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Hypercholesterolemia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: JW Pharmaceutical 2 of 17 · Shenzhen Salubris Pharmaceuticals 4 of 20 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.